Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Manag Res
Asıl Yazarlar: García-González, Xandra, López-Tarruella, Sara, García, María Isabel, González-Haba, Eva, Blanco, Carolina, Salvador-Martin, Sara, Jerez, Yolanda, Thomas, Fabienne, Jarama, María, Sáez, María Sanjurjo, Martín, Miguel, López-Fernández, Luis Andrés
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2018
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190816/
https://ncbi.nlm.nih.gov/pubmed/30349384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S174470
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller